PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Clinical trial

NCT05987956

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 2/3 TRIAL

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

ClinicalTrials.gov

This is a Phase 2/3 registry record with no reported results; it describes a planned pharmacogenomics study exploring SNP associations with alectinib efficacy and toxicity in ALK-positive NSCLC, currently active but not recruiting.

PreliminaryAlectinib Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair ALK Positive Non Small Cell Lung Cancer (NSCLC)

Reported

Planned sample size600

PhasePhase 2/Phase 3

Primary outcome measure 1Measure and Report Alectinib Drug Targets'…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support